GlassScriptPhysician profile
Ronald Demasi
NPI 1528139086
$10,823.03
in general payments reported to CMS, 2019-2025
34 companies · $2,043 in 2025
The $2,043 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $875 · 2020: $687 · 2021: $803 · 2022: $958 · 2023: $3,480 · 2024: $1,977 · 2025: $2,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,826 · Travel and Lodging: $1,469 · Education: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,825.78 |
| Travel and Lodging | $1,469.01 |
| Education | $205.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $2,275.74 | 2020-2024 | Axonics, Bulkamid |
| Janssen Biotech, INC. | $1,723.73 | 2020-2025 | Tremfya, Stelara, Simponi |
| Medtronic, INC. | $1,021.48 | 2022-2025 | Interstim |
| Abbvie INC. | $877.33 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $718.14 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $586.44 | 2019-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $505.44 | 2019-2025 | |
| Boston Scientific Corporation | $326.24 | 2019-2025 | Watchman Access System, Cre Pro, Superion Indirect Decompression System |
| Madrigal Pharmaceuticals | $238.90 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $213.11 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $187.85 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $186.50 | 2024-2025 | Omvoh |
| Medtronic USA, INC. | $186.47 | 2020 | |
| Celgene Corporation | $181.18 | 2021-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $174.58 | 2021-2023 | Zeposia |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $164.81 | 2020-2025 | |
| Fujifilm Healthcare Americas Corporation | $158.66 | 2025 | |
| Braintree Laboratories, INC. | $151.59 | 2019-2025 | Suflave, Sutab |
| Merck Sharp & Dohme LLC | $148.35 | 2019-2023 | Dificid, Zinplava |
| Ucb, INC. | $146.69 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $145.88 | 2019-2022 | |
| Ethicon US, LLC | $108.56 | 2019 | |
| Ardelyx, INC. | $75.92 | 2024-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $54.80 | 2020-2022 | |
| Allergan, INC. | $52.82 | 2019 | |
| Vivus LLC | $45.84 | 2025 | Pancreaze |
| Ferring Pharmaceuticals INC. | $31.62 | 2021-2023 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $29.63 | 2022 | |
| Qol Medical, LLC | $25.68 | 2022 | |
| Lucid Diagnostics INC. | $19.26 | 2023 | |
| Redhill Biopharma INC. | $17.24 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.87 | 2023 | Cyltezo |
| Aimmune Therapeutics, INC. | $15.20 | 2025 | Zenpep |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Demasi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.